Clinical Trial

Pembrolizumab in High-risk Thyroid Cancer

Study acronym: NePenThe
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound aimed at restoring tumor immunosurveillance. The name of this agent is pembrolizumab.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-05-05; most recent amendment 2026-04-15.
Status change: Not Yet Recruiting → Recruiting 2025-04-10
Status change: Recruiting → Not Yet Recruiting 2024-07-08
Status change: Not Yet Recruiting → Recruiting 2024-02-28
Trial Details
NCT Number NCT05852223
Lead Sponsor Istituti Clinici Scientifici Maugeri SpA
Collaborators: Merck Sharp & Dohme LLC
Conditions Differentiated Thyroid Cancer
Enrollment 25 participants
Start Date 2024-12-20
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-04-20